Bonesupport Holding Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Bonesupport Holding wird ein jährliches Gewinn- und Umsatzwachstum von 22.1% bzw. 27.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 33.8% betragen.

Wichtige Informationen

22.1%

Wachstumsrate der Gewinne

21.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	39.3%
Wachstumsrate der Einnahmen	27.1%
Zukünftige Eigenkapitalrendite	33.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Mar 31

Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares

Mar 04

One Bonesupport Holding AB (publ) (STO:BONEX) Analyst Just Cut Their EPS Forecasts

Mar 02

What Kind Of Investors Own Most Of Bonesupport Holding AB (publ) (STO:BONEX)?

Feb 28

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Feb 07

Executive VP of R&D Michael Diefenbeck Just Bought 2.6% More Shares In Bonesupport Holding AB (publ) (STO:BONEX)

Jan 17

The Bonesupport Holding (STO:BONEX) Share Price Has Gained 283%, So Why Not Pay It Some Attention?

Dec 31

Gewinn- und Umsatzwachstumsprognosen

OM:BONEX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,545	474	335	357	2
12/31/2025	1,200	314	331	301	3
12/31/2024	845	149	72	89	2
3/31/2024	656	267	0	7	N/A
12/31/2023	591	245	-24	-18	N/A
9/30/2023	522	214	-40	-37	N/A
6/30/2023	448	-30	-66	-63	N/A
3/31/2023	382	-51	-51	-48	N/A
12/31/2022	329	-68	-50	-47	N/A
9/30/2022	287	-72	-62	-58	N/A
6/30/2022	257	-71	-72	-68	N/A
3/31/2022	234	-82	-81	-77	N/A
12/31/2021	213	-86	-87	-83	N/A
9/30/2021	205	-88	-90	-88	N/A
6/30/2021	198	-96	-89	-87	N/A
3/31/2021	182	-92	-88	-86	N/A
12/31/2020	181	-101	-103	-100	N/A
9/30/2020	174	-115	-121	-117	N/A
6/30/2020	165	-127	-143	-139	N/A
3/31/2020	166	-151	-155	-150	N/A
12/31/2019	155	-161	-168	-164	N/A
9/30/2019	132	-166	-181	-176	N/A
6/30/2019	108	-191	-193	-189	N/A
3/31/2019	98	-182	-180	-177	N/A
12/31/2018	97	-176	-174	-172	N/A
9/30/2018	101	-182	-152	-147	N/A
6/30/2018	119	-146	-133	-128	N/A
3/31/2018	128	-132	-116	-112	N/A
12/31/2017	129	-129	N/A	-108	N/A
9/30/2017	132	-112	N/A	-112	N/A
6/30/2017	126	-124	N/A	-106	N/A
3/31/2017	114	-124	N/A	-103	N/A
12/31/2016	105	-110	N/A	-82	N/A
12/31/2015	62	-60	N/A	-65	N/A
12/31/2014	41	-75	N/A	-46	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BONEXDas prognostizierte Gewinnwachstum (22.1% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: BONEXDie Erträge des Unternehmens (22.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14.1% pro Jahr).

Hohe Wachstumserträge: BONEXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: BONEXDie Einnahmen des Unternehmens (27.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.8% pro Jahr).

Hohe Wachstumseinnahmen: BONEXDie Einnahmen des Unternehmens (27.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BONEXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (33.8%)

Bonesupport Holding Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 14%

Price target increased by 14% to kr293

Consensus EPS estimates fall by 24%, revenue upgraded

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Forecast breakeven date moved forward to 2023

Recent updates

Consensus EPS estimates fall by 14%

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Insider recently sold kr478k worth of stock

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock

Third quarter 2021 earnings released

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Bonesupport Announces Supplementary US Denovo Application Submitted

Chief Executive Officer recently bought kr343k worth of stock

Price target decreased to kr65.00

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Insider recently bought kr401k worth of stock

Chairman of the board recently bought kr1.6m worth of stock

Second quarter 2021 earnings released

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr210k worth of stock